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Human Herpes simplex virus 'types 1, 2 (HSV1 and HSV2) and
Varicella Zoster virus (VZV) infections are the most common viral
infections detected in viral diagnostic laboratories. The aim of this
study was to evaluate a newly introduced LightCycler multiplex real-
time PCR (LCmPCR) kit (Roche, Australia) for the detection and
differentiation of HSV1, 2 and VZV, against our existing nested
multiplex PCR (nmPCR) which detects HSV1, HSV2, VZV, CMV,
EBV and Enterovirus, and our one-step multiplex PCR (mPCR),
which detects HSV1, HSV2, VZV and Adenovirus.
A total of 228 specimens were assessed, 43 using all three
LmPCR, mPCR and nmPCR with identical results for the 12/43
positive and 31/43 negative specimens. We tested 124 clinical
specimens using the LCmPCR and mPCR in parallel, and detected
9/124 HSV1 (7.26%), 15/124 HSV2 (12.1%) and 13/124 VZV
(11.4%), with 100% correlation between the two assays. We tested
147 specimens using the LCmPCR and nmPCR in parallel, and
detected 7/147 HSV1 (4.76%),6/147 HSV2 (4.08%) and 7/147 VZV
(4.76%) with 100% correlation between these two assays.
LCmPCR showed very good specificity. The sensitivity of LCmPCR
is the same as the one-step mPCR, but less sensitive than two-step
nmPCR on limit of detection testing using dilutions of DNA
extracted from cell culture material.
The LCmPCR offers specificity, sensitivity combined with rapid (two
hour) quantitative detection and differentiation of HSV1, HSV2 and
VZV. Although nmPCR is a more sensitive method, allowing
detection of more virus species, it takes two-working days to obtain
results. LCmPCR is particularly helpful for rapid turnaround and for
guiding therapy.
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MassTag PCR is a novel technology for the rapid, sensitive and
simultaneous detection of multiple gene sequences. This technique,
developed at the Center for Infection and Immunity (CII) at
Columbia University, utilises a library of unique molecular tags,
each unique in its molecular weight. MassTags are conjugated to
oligonucleotide primers using a UV-cleavable linker that enables
separation of primer and tag. Different primers are labelled each
with a different molecular weight tag and are used to amplify target
nucleic acids in a multiplex RT-PCR. After removing unincorporated
primers, tags are released by UV irradiation and analysed by mass
spectrometry. Thus, amplification of the gene target produces a
unique dual signal in mass spectrometric analysis that allows its
identification. MassTag PCR offers an inexpensive and sensitive
diagnostic platform suitable for high-throughput testing that can be
adapted to suit diagnostic needs (e.g., syndrome-, vector-based).
To date, MassTag PCR panels have been developed for the
detection of respiratory and tick-borne pathogens, and viruses that
cause haemorrhagic fever. An additional MassTag PCR assay is
being developed to identify microbial agents that cause neurological
disease in a North AmericanlEuropean diagnostic setting. In
collaboration with the CII and PathWest Laboratory Medicine, we
have begun modifying and developing this assay to address
pathogens relevant to the Australasian region. Initial research has
involved extensive bioinformatics analyses for the design of primer
sets that are specific only for the cognate target pathogen and that
will not cross-hybridise with existing primers comprising the pa
This has been followed by in vitro evaluation of multiplex pa
using untagged primers and agarose gel analysis. Prelimi
research experiences and progress towards development of
assay will be presented.
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Rabies virus, the genotype 1 (gt1) Iyssavirus, is found througl
Africa and worldwide - Australia being a notable excepti
harboring only the Australian bat Iyssavirus (gt7). Three additi
Iyssavirus genotypes are exclusive to Africa. These are Lagos
virus (LBV, gt2), Mokola virus (MOKV, gt3) and Duvenhage
(DUW, gt4). Both LBV and DUW have been associated .
reservoirs - LBV appears to primarily circulate in frugivorous
and DUW in insectivorous bats. However, little is known abou.
activity and distribution of these viruses and few isolates have
made over past decades. Recently, we have embarked on p.
as well as active surveillance for these bat-associated ra
related Iyssaviruses. We tested samples from frugivorous
insectivorous bats (brain, serum, oral swabs) collected duri~
field excursions or obtained from museums, bat interest grou
veterinary diagnostic laboratories, for the presence of lyssa .
Brain samples were tested for viral antigen (fluorescent a
test, FAT) and oral swabs for viral RNA (nested RT-PCR).
samples were tested for Iyssavirus antibodies using a
fluorescent focus inhibition test (RFFIT).
Six new isolates of LBV have been recovered from fruqlvoroes
species and characterized with regard to nucleoprotein seq
These isolations followed a period of 13 years in which LBV
been encountered in South Africa, demonstrating active
cycles and the value of targeted surveillance for such vi
addition, oral swabs collected from bats that were positive b
also tested positive for the presence of viral RNA, confirrnst;
likely involvement of saliva in virus transmission. Regr:::
serology we have, in tandem with related studies, con::
surprisingly high rates of seropositivity among healthy anirna
findings re-emphasize a lack of surveillance and understa
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